442 related articles for article (PubMed ID: 2938852)
1. Ganglioside loading of cultured fibroblasts: a provocative method for the diagnosis of the GM2 gangliosidoses.
Charrow J; Binns HJ
Clin Chim Acta; 1986 Apr; 156(1):41-9. PubMed ID: 2938852
[TBL] [Abstract][Full Text] [Related]
2. Plasma G
Blondel A; Kraoua I; Marcelino C; Khrouf W; Schlemmer D; Ganne B; Caillaud C; Fernández-Eulate G; Turki IBY; Dauriat B; Bonnefont-Rousselot D; Nadjar Y; Lamari F
Mol Genet Metab; 2023 Feb; 138(2):106983. PubMed ID: 36709536
[TBL] [Abstract][Full Text] [Related]
3. Assay of the GM2-ganglioside cleaving hexosaminidase activity of skin fibroblasts for GM2-gangliosidoses.
Harzer K
Clin Chim Acta; 1983 Nov; 135(1):89-93. PubMed ID: 6228344
[No Abstract] [Full Text] [Related]
4. AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2.
Conzelmann E; Sandhoff K
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3979-83. PubMed ID: 99746
[TBL] [Abstract][Full Text] [Related]
5. GM2-ganglioside metabolism in hexosaminidase A deficiency states: determination in situ using labeled GM2 added to fibroblast cultures.
Raghavan SS; Krusell A; Krusell J; Lyerla TA; Kolodny EH
Am J Hum Genet; 1985 Nov; 37(6):1071-82. PubMed ID: 2934978
[TBL] [Abstract][Full Text] [Related]
6. GM2-ganglioside metabolism in cultured human skin fibroblasts: unambiguous diagnosis of GM2-gangliosidosis.
Raghavan S; Krusell A; Lyerla TA; Bremer EG; Kolodny EH
Biochim Biophys Acta; 1985 Apr; 834(2):238-48. PubMed ID: 3995063
[TBL] [Abstract][Full Text] [Related]
7. Incorporation and metabolism of ganglioside GM2 in skin fibroblasts from normal and GM2 gangliosidosis subjects.
Sonderfeld S; Conzelmann E; Schwarzmann G; Burg J; Hinrichs U; Sandhoff K
Eur J Biochem; 1985 Jun; 149(2):247-55. PubMed ID: 3922757
[TBL] [Abstract][Full Text] [Related]
8. Western blotting analysis of the beta-hexosaminidase alpha- and beta-subunits in cultured fibroblasts from cases of various forms of GM2 gangliosidosis.
Utsumi K; Tsuji A; Kase R; Tanaka A; Tanaka T; Uyama E; Ozawa T; Sakuraba H; Komaba Y; Kawabe M; Iino Y; Katayama Y
Acta Neurol Scand; 2002 Jun; 105(6):427-30. PubMed ID: 12027830
[TBL] [Abstract][Full Text] [Related]
9. Ganglioside GM2 N-acetyl-beta-D-galactosaminidase and asialo GM2 (GA2) N-acetyl-beta-D-galactosaminidase; studies in human skin fibroblasts.
O'Brien JS; Norden GW; Miller AL; Frost RG; Kelly TE
Clin Genet; 1977 Mar; 11(3):171-83. PubMed ID: 13950
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
Tsuji D; Higashine Y; Matsuoka K; Sakuraba H; Itoh K
Clin Chim Acta; 2007 Mar; 378(1-2):38-41. PubMed ID: 17196574
[TBL] [Abstract][Full Text] [Related]
11. High-resolution loading tests in the study of genetic heterogeneity in gangliosidosis fibroblasts.
Akhunov VS; Mirenburg TV; Krasnopolskaya XD
J Inherit Metab Dis; 1994; 17(1):104-11. PubMed ID: 8051915
[TBL] [Abstract][Full Text] [Related]
12. Neurophysiological investigations in GM1 and GM2 gangliosidoses.
Pampiglione G; Harden A
Neuropediatrics; 1984 Sep; 15 Suppl():74-84. PubMed ID: 6100798
[TBL] [Abstract][Full Text] [Related]
13. Intracellular degradation of sulforhodamine-GM1: use for a fluorescence-based characterization of GM2-gangliosidosis variants in fibroblasts and white blood cells.
Agmon V; Khosravi R; Marchesini S; Dinur T; Dagan A; Gatt S; Navon R
Clin Chim Acta; 1996 Mar; 247(1-2):105-20. PubMed ID: 8920231
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/nCas9-Based Genome Editing on GM2 Gangliosidoses Fibroblasts via Non-Viral Vectors.
Leal AF; Cifuentes J; Quezada V; Benincore-Flórez E; Cruz JC; Reyes LH; Espejo-Mojica AJ; Alméciga-Díaz CJ
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142595
[TBL] [Abstract][Full Text] [Related]
15. Molecular forms of GM2-activator protein. A study on its biosynthesis in human skin fibroblasts.
Burg J; Banerjee A; Sandhoff K
Biol Chem Hoppe Seyler; 1985 Sep; 366(9):887-91. PubMed ID: 3935131
[TBL] [Abstract][Full Text] [Related]
16. Classification of disorders of GM2 ganglioside hydrolysis using 3H-GM2 as substrate.
Novak A; Callahan JW; Lowden JA
Biochim Biophys Acta; 1994 Mar; 1199(2):215-23. PubMed ID: 8123671
[TBL] [Abstract][Full Text] [Related]
17. Deficiency of the hexosaminidase A activator protein in a case of GM2 gangliosidosis; variant AB.
Hechtman P; Gordon BA; Ng Ying Kin NM
Pediatr Res; 1982 Mar; 16(3):217-22. PubMed ID: 6801612
[TBL] [Abstract][Full Text] [Related]
18. [Biosynthesis and biodegradation of GM2 ganglioside].
Hirabayashi Y; Kasakura H; Matsumoto M
Tanpakushitsu Kakusan Koso; 1984 Sep; 29(9):708-22. PubMed ID: 6240072
[No Abstract] [Full Text] [Related]
19. Recombinant GM2-activator protein stimulates in vivo degradation of GA2 in GM2 gangliosidosis AB variant fibroblasts but exhibits no detectable binding of GA2 in an in vitro assay.
Bierfreund U; Lemm T; Hoffmann A; Uhlhorn-Dierks G; Childs RA; Yuen CT; Feizi T; Sandhoff K
Neurochem Res; 1999 Feb; 24(2):295-300. PubMed ID: 9972878
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses.
Kobayashi T; Goto I; Okada S; Orii T; Ohno K; Nakano T
J Neurochem; 1992 Oct; 59(4):1452-8. PubMed ID: 1402895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
